Association between the levels of adherence to evidence-based drug therapies for secondary prevention after an acute myocardial infarction (MI) and the incidence of a new MI: a comparison between ‘time-dependent’ and ‘time-independent’ sampling methods
| Time-dependent sampling | Time-independent sampling | |||||
|---|---|---|---|---|---|---|
| OR | CI 95% | p Value | OR | CI 95% | p Value | |
| Antiplatelet agents | ||||||
| 0≤PDC≤0.5 | 1.00 | – | – | 1.00 | – | – |
| 0.5<PDC≤0.75 | 0.82 | 0.59 to 1.16 | 0.261 | 0.81 | 0.56 to 1.16 | 0.245 |
| PDC>0.75 | 0.63 | 0.48 to 0.84 | 0.001 | 0.93 | 0.69 to 1.25 | 0.618 |
| β-Blockers | ||||||
| 0≤PDC≤0.25 | 1.00 | – | – | 1.00 | – | – |
| 0.25<PDC≤0.5 | 0.95 | 0.70 to 1.28 | 0.722 | 1.11 | 0.82 to 1.51 | 0.508 |
| PDC>0.5 | 0.68 | 0.49 to 0.94 | 0.018 | 1.23 | 0.89 to 1.72 | 0.211 |
| ACE-inhibitors/ARBs | ||||||
| 0≤PDC≤0.5 | 1.00 | – | – | 1.00 | – | – |
| 0.5<PDC≤0.75 | 0.83 | 0.57 to 1.21 | 0.343 | 0.96 | 0.65 to 1.43 | 0.858 |
| PDC>0.75 | 0.72 | 0.55 to 0.95 | 0.018 | 1.00 | 0.76 to 1.33 | 0.977 |
| Statins | ||||||
| 0≤PDC≤0.5 | 1.00 | – | – | 1.00 | – | – |
| 0.5<PDC≤0.75 | 0.79 | 0.48 to 1.31 | 0.367 | 0.78 | 0.47 to 1.28 | 0.326 |
| PDC>0.75 | 0.76 | 0.55 to 1.05 | 0.100 | 0.86 | 0.62 to 1.20 | 0.376 |
Potential confounders included in the analysis: percutaneous coronary intervention and bypass at the index admission, heart failure, diabetes, chronic nephropathies, diseases of arteries, arterioles and capillaries, ACE-inhibitors/ARBs before admission, duration of the index admission and concomitant ‘evidence-based’ therapy.
ARBs, angiotensin receptor blockers; PDC, proportion of days covered.